Buchumschlag

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Background - Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy is currently unknown. In the GeparNuevo (NCT02685059) trial, addition of durvalumab to NACT as previously reported led to a mod...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Loibl, Sibylle (VerfasserIn) , Schneeweiss, Andreas (VerfasserIn) , Huober, J. (VerfasserIn) , Braun, M. (VerfasserIn) , Rey, J. (VerfasserIn) , Blohmer, J. -U. (VerfasserIn) , Furlanetto, J. (VerfasserIn) , Zahm, D. -M. (VerfasserIn) , Hanusch, C. (VerfasserIn) , Thomalla, J. (VerfasserIn) , Jackisch, C. (VerfasserIn) , Staib, P. (VerfasserIn) , Link, T. (VerfasserIn) , Rhiem, K. (VerfasserIn) , Solbach, C. (VerfasserIn) , Fasching, P. A. (VerfasserIn) , Nekljudova, V. (VerfasserIn) , Denkert, C. (VerfasserIn) , Untch, M. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 9 August 2022
In: Annals of oncology
Year: 2022, Jahrgang: 33, Heft: 11, Pages: 1149-1158
ISSN:1569-8041
DOI:10.1016/j.annonc.2022.07.1940
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.annonc.2022.07.1940
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753422037917
Volltext
Verfasserangaben:S. Loibl, A. Schneeweiss, J. Huober, M. Braun, J. Rey, J.-U. Blohmer, J. Furlanetto, D.-M. Zahm, C. Hanusch, J. Thomalla, C. Jackisch, P. Staib, T. Link, K. Rhiem, C. Solbach, P.A. Fasching, V. Nekljudova, C. Denkert & M. Untch, on behalf of GBG and AGO-B
Beschreibung
Zusammenfassung:Background - Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy is currently unknown. In the GeparNuevo (NCT02685059) trial, addition of durvalumab to NACT as previously reported led to a moderate increase in pathological complete response (pCR) rate by an absolute 9% (P = 0.287). - Patients and methods - Patients with cT1b-cT4a-d triple-negative breast cancer (TNBC) received durvalumab 1.5 g or placebo every 4 weeks added to nab-paclitaxel 125 mg/m2 weekly for 12 weeks, followed by durvalumab/placebo every 4 weeks plus epirubicin/cyclophosphamide every 2 weeks followed by surgery. Durvalumab was not continued after surgery. The primary objective was pCR. Secondary endpoints included invasive disease-free survival (iDFS), distant disease-free survival (DDFS) and overall survival (OS). - Results - A total of 174 patients were randomised between June 2016 and October 2017. After a median follow-up of 43.7 months, 34 events had occurred. Despite a non-significant increase in the pCR rate, significant differences were observed for 3-year iDFS, DDFS and OS: iDFS was 85.6% with durvalumab versus 77.2% with placebo [hazard ratio (HR) 0.48, 95% confidence interval (CI) 0.24-0.97, stratified log-rank P = 0.036]; DDFS 91.7% versus 78.4% (HR 0.31, 95% CI 0.13-0.74, P = 0.005); OS 95.2% versus 83.5% (HR 0.24, 95% CI 0.08-0.72, P = 0.006). pCR patients had 3-year iDFS of 95.5% with durvalumab and 86.1% without (HR 0.22, 95% CI 0.05-1.06). In the non-pCR cohort 3-year iDFS was 76.3% versus 69.7% (HR 0.67, 95% CI 0.29-1.54). Multivariable analysis confirmed a durvalumab effect independent of the pCR effect. No new safety signals occurred. - Conclusions - Durvalumab added to NACT in TNBC significantly improved survival despite a modest pCR increase and no adjuvant component of durvalumab. Additional studies are needed to clarify the optimal duration and sequence of checkpoint inhibitors in the treatment of early TNBC.
Beschreibung:Gesehen am 19.01.2023
Beschreibung:Online Resource
ISSN:1569-8041
DOI:10.1016/j.annonc.2022.07.1940

Ähnliche Einträge